Cameron Durrant is a pharmaceutical and biotech executive and entrepreneur. He trained and practiced medicine in Wales and Australia, before embarking on a pharmaceuticals career, initially with Merck and GSK in the UK, where he held sales, marketing and business development roles. He subsequently held staff and line international and US domestic responsibility for businesses at Pharmacia Corporation (until its acquisition by Pfizer) and Johnson and Johnson. He has been CEO/Chairman/CFO for four companies, two of which were public, one of which he founded and took public. He has been involved in five exits and raised over $50MM in investment funding. He has launched 20 brands, nationally, regionally and globally, including five which sold >$1Bn annually and one >$3Bn annually; three brands were nominated for Prix Galien awards. He was an Ernst + Young ‘Entrepreneur Of The Year’ national finalist, and named in the annual ‘100 Most Inspiring Leaders in Pharma’ published by PharmaVoice on 3 separate occasions. Most recently, Cameron served as a corporate officer of Hi-Tech Pharmacal (recently sold to Akorn) and CEO of the ECR division (subsequently divested by Akorn to Valeant). Cameron earned his medical degree from the Welsh National School of Medicine, Cardiff, UK, his DRCOG from the Royal College of Obstetricians and Gynecologists, London, UK, his MRCGP from the Royal College of General Practitioners, London, UK, and his DipCH from the Melbourne Academy, Australia and his Master of Business Administration from Henley Management College, Oxford, UK. He is currently on the board of two private medical device companies and a founding board member of a private nanotech/oncology company.